Scientist I/II, Gene Therapy Development (Virologist) - United States
Want to know company name or location? Company managed [?]
- We are seeking motivated and creative individuals to join our Gene Therapy (GT) cell engineering team.
- The GT Development group is focused on delivering effective viral therapeutics to patients with unmet medical needs.
- The successful candidate will join a team dedicated to early stage development of viral therapeutics and contribute to ongoing efforts to develop production platforms using molecular biology and cellular engineering techniques.
- A background in viral propagation and knowledge of the molecular components involved with virus production will be highly valued.
- Candidates with experience and training in virology, cell engineering, expression design, or high-throughput techniques will be preferred.
- Qualifications include training in virology, molecular biology, biochemistry, or similar discipline.
- The ability to perform productively and efficiently within a dynamic work environment along with strong verbal and written communication skills is also desired.
A PhD in virology, bio-engineering, molecular biology or related field with 1-3 years of post-graduate training; or MS with 6-9 years of industry experience.
- Through cutting-edge science and medicine, our company discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases.
- Our company is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis (MS), has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS).
- Our company also manufactures and commercializes biosimilars of advanced biologics.
- Our global organization of nearly 7,000 employees is committed to a single mission: making a meaningful difference in the lives of patients with few or no treatment options.
- Our company was founded in 1978 and today serves patients in nearly 70 countries.
- We aspire to have the greatest impact on patients and science of any biotechnology company in the history of our industry.
- To us, that means creating novel medicines that benefit individuals and society, and bringing new scientific understanding to diseases for which there are no adequate treatments.
- For nearly two decades our company has led in the research and development of new therapies to treat MS, including the most prescribed oral treatment in the world.
- Now our research is driving revolutionary new MS treatments with the goal of reversing or even repairing damage caused by the disease.
- We are now applying our neurological expertise to solve some of most challenging and complex diseases of the brain, including Alzheimer’s disease, Parkinson’s disease, and ALS.
- As we uncover new insights into human biology, our company is employing cutting-edge technologies to discover potential treatments for rare and genetic disorders.
- Our company is revolutionizing biologic manufacturing, developing the industry’s most advanced plants and processes.
- This expertise is used to produce both original innovative therapies and bio similar that expand patient access to lower-cost medicines.
Our Corporate Citizenship
- The same intellectual discipline and passion that drives our science is reflected in our corporate citizenship, environmental sustainability, and commitment to diversity and inclusion.
- As a company, we are focused on improving science education and limiting the impact of our company on the environment.
Job Segment: Scientific, Biochemistry, Biomedical Engineering, Biotech, Engineer, Engineering, Science